XYRATEX LTDNOTES TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(U.S. dollars and amounts in thousands, except per share data, unless otherwise stated)4. Acquisition and purchase of intangible assets (Continued)actually have been reported if the acquisition had actually occurred at the beginning of the periodspresented or that may be reported in the future.Unaudited Pro FormaYear Ended November 30,2004 2003Revenue .................................................... $463,808 $357,997Net income (loss) from continuing operations ......................... $(121,469) $(34,460)Net income (loss) from continuing operations per common share, class Bpreferred ordinary and class B ordinary share, basic and diluted .......... $ (6.67) $ (9.24)Beyond3On September 2, 2004 the Company acquired the intellectual property of Beyond3, a developer ofadvanced optical inspection systems based in San Jose, California. The structure of the transactioninvolves an initial cash consideration of $1,402, including acquisition costs of $102, plus future paymentsof which $1,200 is based on the achievement of certain product delivery milestones and furtheramounts up to $16,000 are based on forty to sixty percent of operating profit for the four years endingNovember 30, 2008. No additional amounts had been paid or were payable at November 30, 2005.Beyond3 was a privately run business engaged in the business of providing test solution products tomanufacturers of disk drives. The Company’s primary reason for the acquisition was to broaden itsexpertise and product range within its Storage Infrastructure segment.This acquisition has been accounted for as a purchase of assets and therefore no element of thepurchase price is allocated to goodwill. The Company has estimated the fair values of the acquiredassets and liabilities. The preliminary allocation of the purchase price to tangible and intangible assetsis as follows:Identifiable intangible assets:Patents and core technology .................................. 387In process research and development ........................... 852Supplier contracts ......................................... 39Assembled workforce ....................................... 124Initial purchase price ........................................ $1,402The value attributable to in-process research and development (‘‘IPR&D’’) was recorded as anoperating expense on the acquisition date because the acquired technology had not reachedtechnological feasibility and had no alternative uses. The value was determined by estimating the coststo develop the acquired IPR&D into commercially viable products, estimating the resulting after-taxnet cash flows (‘‘free cash flow’’) from such projects, and discounting the free cash flows back to theirpresent value. The discount rate included a factor that took into account the uncertainty surroundingthe successful development of the acquired IPR&D. These estimates are subject to change, given theuncertainties of the development process, and no assurance can be given that deviations from theseestimates will not occur.F-20
XYRATEX LTDNOTES TO AUDITED CONSOLIDATED FINANCIAL STATEMENTS (Continued)(U.S. dollars and amounts in thousands, except per share data, unless otherwise stated)4. Acquisition and purchase of intangible assets (Continued)Intangible assets are being amortized on a straight line basis for their remaining lives as follows:Patents and core technology ...................................Supplier contracts ..........................................Assembled workforce ........................................The intangible assets are expected to be deductible for tax purposes.6 years3 years4 yearsIdentified intangible assetsIdentified intangible assets balances are summarized as follows:November 30, 2005AccumulatedGross Assets Amortization Net AssetsExisting technology .................. $11,300 $1,906 $ 9,394Core technology .................... 3,400 508 2,892Non-competition agreements ........... 1,000 282 718Order backlog ..................... 2,100 1,209 891Patents and core technology ........... 1,487 131 1,356Supplier contracts ................... 39 16 23Assembled workforce ................ 124 39 85Customer relationships ............... 4,300 289 4,011Total ......................... $23,750 $4,380 $19,370On the basis that no impairment charges are required, the Company expects to recordamortization of these intangible assets in its statements of operations as follows:Amortization2006 .................................................. $4,7392007 .................................................. 4,3252008 .................................................. 3,1402009 .................................................. 2,6792010 .................................................. 2,386Thereafter ............................................. $2,101F-21
- Page 3:
XYRATEX LTDANNUAL REPORT FOR THE YE
- Page 6 and 7:
INTRODUCTIONWe are incorporated und
- Page 8 and 9:
Year Ended November 30,2005 2004 20
- Page 10 and 11:
The computations for the weighted a
- Page 12 and 13:
The markets in which we operate are
- Page 14 and 15:
technological capabilities. This co
- Page 16 and 17:
may cease production of components,
- Page 18 and 19:
• potentially adverse tax consequ
- Page 20 and 21:
We could incur substantial costs, i
- Page 22 and 23:
influence by voting at a meeting of
- Page 24 and 25:
Xyratex Ltd to the former sharehold
- Page 26 and 27:
In addition to the rapid growth of
- Page 28 and 29:
RAID controller technology is proje
- Page 30 and 31:
Our Competitive StrengthsDisk drive
- Page 32 and 33:
the storage subsystem and disk driv
- Page 34 and 35:
Our storage subsystems are internal
- Page 36 and 37:
systems are capable of testing a fu
- Page 38 and 39:
Research and DevelopmentWe have ove
- Page 40 and 41:
• sets forth procedures for the p
- Page 42 and 43:
Item 4C: Organization StructureXyra
- Page 44 and 45:
ecame the parent company of our bus
- Page 46 and 47:
Foreign Exchange Rate FluctuationsT
- Page 48 and 49:
we recorded in the year ended Novem
- Page 50 and 51:
Fiscal Year Ended November 30, 2005
- Page 52 and 53:
Research and Development—otherThe
- Page 54 and 55:
Fiscal Year Ended November 30, 2004
- Page 56 and 57:
Selling, General and Administrative
- Page 58 and 59:
Quarterly Results of OperationsThe
- Page 60 and 61: sales growth. The increase in defer
- Page 62 and 63: choose to make or alliances we have
- Page 64 and 65: compete. Identifiable intangible as
- Page 66 and 67: ITEM 6: DIRECTORS, SENIOR MANAGEMEN
- Page 68 and 69: Ernest Sampias has served as a dire
- Page 70 and 71: Audit CommitteeOur Audit Committee
- Page 72 and 73: Employee Benefit/Share Option Plans
- Page 74 and 75: The maximum amount that any partici
- Page 76 and 77: Restricted StockRestricted stock aw
- Page 78 and 79: the options, warrants or rights, bu
- Page 80 and 81: Quarterly high and low market price
- Page 82 and 83: whose functional currency is not th
- Page 84 and 85: on the Nasdaq National Market and,
- Page 86 and 87: Interest RatesWe had cash and cash
- Page 88 and 89: aggregate in any fiscal year and th
- Page 90 and 91: (This page has been left blank inte
- Page 92 and 93: XYRATEX LTDAUDITED CONSOLIDATED BAL
- Page 94 and 95: F-4XYRATEX LTDAUDITED CONSOLIDATED
- Page 96 and 97: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 98 and 99: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 100 and 101: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 102 and 103: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 104 and 105: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 106 and 107: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 108 and 109: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 112 and 113: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 114 and 115: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 116 and 117: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 118 and 119: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 120 and 121: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 122 and 123: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 124 and 125: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 126 and 127: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 128 and 129: XYRATEX LTDNOTES TO AUDITED CONSOLI
- Page 130: (This page has been left blank inte